Bristol-Myers Squibb (BMY) to Release Quarterly Earnings on Thursday

Bristol-Myers Squibb (NYSE:BMY) will be posting its quarterly earnings results before the market opens on Thursday, October 25th. Analysts expect Bristol-Myers Squibb to post earnings of $0.89 per share for the quarter. Bristol-Myers Squibb has set its FY18 guidance at $3.55-3.65 EPS.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 26th. The biopharmaceutical company reported $1.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.87 by $0.14. Bristol-Myers Squibb had a return on equity of 42.58% and a net margin of 1.74%. The firm had revenue of $5.70 billion for the quarter, compared to analyst estimates of $5.48 billion. During the same quarter in the prior year, the company earned $0.74 EPS. Bristol-Myers Squibb’s revenue was up 10.9% on a year-over-year basis. On average, analysts expect Bristol-Myers Squibb to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

BMY opened at $58.90 on Thursday. Bristol-Myers Squibb has a 12-month low of $49.96 and a 12-month high of $70.05. The company has a current ratio of 1.40, a quick ratio of 1.28 and a debt-to-equity ratio of 0.46. The stock has a market cap of $101.47 billion, a P/E ratio of 19.24, a PEG ratio of 1.70 and a beta of 0.98.

The company also recently announced a quarterly dividend, which will be paid on Thursday, November 1st. Investors of record on Friday, October 5th will be paid a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 2.72%. The ex-dividend date of this dividend is Thursday, October 4th. Bristol-Myers Squibb’s payout ratio is 53.16%.

Several equities analysts recently issued reports on the company. SunTrust Banks reissued a “buy” rating and set a $67.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, July 31st. JPMorgan Chase & Co. increased their target price on Bristol-Myers Squibb from $70.00 to $74.00 and gave the stock an “overweight” rating in a research note on Monday, October 8th. ValuEngine raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Saturday, July 14th. BMO Capital Markets increased their target price on Bristol-Myers Squibb from $47.00 to $51.00 and gave the stock a “market perform” rating in a research note on Monday, July 23rd. Finally, Credit Suisse Group increased their target price on Bristol-Myers Squibb from $58.00 to $61.00 and gave the stock a “neutral” rating in a research note on Friday, July 27th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and seven have issued a buy rating to the company. Bristol-Myers Squibb has an average rating of “Hold” and a consensus price target of $63.13.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Recommended Story: Diversification in Your Portfolio

Earnings History for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply